| Autor: |
Thorek DLj; Department of Radiology, Memorial Sloan-Kettering Cancer Center New York, New York., Robertson R, Bacchus WA, Hahn J, Rothberg J, Beattie BJ, Grimm J |
| Jazyk: |
angličtina |
| Zdroj: |
American journal of nuclear medicine and molecular imaging [Am J Nucl Med Mol Imaging] 2012; Vol. 2 (2), pp. 163-73. Date of Electronic Publication: 2012 Mar 28. |
| Abstrakt: |
Cerenkov luminescence imaging (CLI) is an emerging hybrid modality that utilizes the light emission from many commonly used medical isotopes. Cerenkov radiation (CR) is produced when charged particles travel through a dielectric medium faster than the speed of light in that medium. First described in detail nearly 100 years ago, CR has only recently applied for biomedical imaging purposes. The modality is of considerable interest as it enables the use of widespread luminescence imaging equipment to visualize clinical diagnostic (all PET radioisotopes) and many therapeutic radionuclides. The amount of light detected in CLI applications is significantly lower than other that in other optical imaging techniques such as bioluminescence and fluorescence. However, significant advantages include the use of approved radiotracers and lack of an incident light source, resulting in high signal to background ratios. As well, multiple subjects may be imaged concurrently (up to 5 in common bioluminescent equipment), conferring both cost and time benefits. This review summarizes the field of Cerenkov luminescence imaging to date. Applications of CLI discussed include intraoperative radionuclide-guided surgery, monitoring of therapeutic efficacy, tomographic optical imaging capabilities, and the ability to perform multiplexed imaging using fluorophores excited by the Cerenkov radiation. While technical challenges still exist, Cerenkov imaging has materialized as an important molecular imaging modality. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
